What Evidence Shows About Tysabri PML Risk After Stopping Treatment
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Specific Risks
If you or a loved one took Tysabri and stopped treatment, you may wonder whether the risk of progressive multifocal leukoencephalopathy (PML) continues. Decades of pharmacovigilance and clinical research have established that PML risk does not vanish immediately after discontinuation, and understanding this timeline is critical for informed decision-making. This page summarizes the evidence on PML risk after stopping Tysabri, including what the science can and cannot tell us.
Understanding Tysabri and Its Link to PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is an infection of the brain's white matter that typically occurs only in immunocompromised individuals. In patients treated with Tysabri, PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in some cases, seizures. Diagnosis is confirmed through brain MRI showing characteristic lesions and detection of JC virus DNA in cerebrospinal fluid. Three specific risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies in the blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are antibody negative. The risk increases with cumulative exposure to Tysabri, particularly after 24 months of therapy. Additionally, patients who have previously taken immunosuppressive drugs, such as mitoxantrone, cyclophosphamide, or azathioprine, face an elevated risk.
Mechanism of PML Development and Risk Factors
The mechanistic pathway linking Tysabri to PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing them from crossing the blood-brain barrier into the central nervous system. This reduces inflammation in the brain, which is beneficial for multiple sclerosis, but it also impairs normal immune surveillance. The JC virus, which is latent in most people, can reactivate and spread to the brain when immune cells are unable to patrol the central nervous system effectively. This loss of immune control allows the virus to infect oligodendrocytes, the cells that produce myelin, leading to the demyelination characteristic of PML. The adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The FDA-approved prescribing information includes a boxed warning that states Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML. Despite these warnings, some patients and their families have alleged that the risks were not adequately communicated or that the drug's manufacturer failed to provide sufficient guidance on risk stratification and monitoring.
Settlement Considerations for Florida Patients
Settlement-related considerations for affected patients in Florida involve several factors. The timeline between exposure to Tysabri and documented harm is critical. In clinical trials, PML occurred in three patients: two with multiple sclerosis who had received Tysabri for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can develop after varying durations of treatment, sometimes within months. For patients who develop PML, the consequences are often catastrophic, leading to permanent neurological deficits or death. Legal claims may focus on whether the prescribing physician was adequately informed about risk factors, whether appropriate monitoring was performed, and whether the patient was informed of the potential for PML before starting therapy. Patients in Florida who have been diagnosed with PML after using Tysabri may be eligible to pursue compensation through settlements or litigation. The strength of a claim often depends on evidence that the drug's warnings were insufficient or that the manufacturer failed to update risk information as new data emerged. Additionally, the presence of anti-JCV antibodies and duration of therapy are key factors in assessing whether the risk was foreseeable. Legal counsel experienced in pharmaceutical injury cases can evaluate individual circumstances, including medical records, treatment history, and the timing of diagnosis relative to Tysabri exposure.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and how is it linked to PML?
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the risk factors for developing PML while on Tysabri?
Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Can Florida patients who developed PML after Tysabri seek compensation?
Yes, Florida patients diagnosed with PML after Tysabri use may be eligible for compensation through settlements or litigation. Claims often involve adequacy of warnings and risk communication. Legal counsel can evaluate individual cases.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Treatment for severe Progressive Multifocal Leukoencephalopathy after Tysabri
- New Jersey Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
- Statute of limitations for Tysabri in Georgia
- FDA warning Tysabri Progressive Multifocal Leukoencephalopathy
- Statute of limitations for Tysabri in California
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.